ZYME · Zymeworks Inc.

28.16

USD

-0.61 (-2.12%)

25/08/2026 11:16:23 AM

Price change (7D)

Unlock stock Insights

Create a free account to unlock price targets, recommendations, and commentary.

Overview

Market Cap

US$2.04B

0.00

EV/EBITDA

N/A

DIV Yield

0%

Payout Ratio

0%

MQV Rating

3Neutral

As at 25/08/2026 11:16:23 AM

Price Chart

Description

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

All-Companies
All-Consensus
Big Candle (Realtime)
Consensus Cheap
Defying Gravity
Engulfing Bearish
Engulfing Bearish (Realtime)
HALO All
HALO Balance Sheet
HALO Capital Efficiency
HALO Price Momentum
Hammer Bearish (Realtime)
Near Resistance
Near Resistance (Realtime)

Key Fundamentals

EPS 3 yr Growth

-156.40%

EBITDA Margin

-77.20%

Operating Cashflow

-$33m

Free Cash Flow Return

-10.30%

ROIC

-25.40%

Interest Coverage

N/A

Quick Ratio

5.90

Performance

52 weeks range

Low 13.6 - 29.75

Trade Value (12mth)

US$4,424,022.00

1 week

3.14%

1 month

14.92%

YTD

-0.19%

1 year

84.64%

All time high

59.03

Additional Data

Shares Outstanding (Fully Diluted)

73m

HALO Sector

Healthcare

Next Company Report Date

10-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

Consensus

Unlock full consensus

Consensus score

/10

Recommendation

Buy

Target price

Deviation

Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

Mqv

Neutral

Garp

Strong

Mqv Small

Neutral

Momentum

Price

Very Strong

Earnings

Very Weak

Growth

Earnings

Strong

Dividends

Very Weak

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

Valuation

Unlock full dataset

Value

Consensus

Yield

News & Announcements

Date	Event
26 August 26EDG
07 August 26EDG
07 August 26EDG
07 August 26EDG
07 August 26EDG

Key Stakeholders

Name	Title
Nextech Invest AG	Private Company
Gregory A. Ciongoli	Individual
Kenneth Harry Galbraith	Individual
Mark Hollywood	Individual
Paul A. Moore	Individual